Short name: B22956, generic name: Gadocoletic acid, chemical compound: Gadocoletic acid trisodium salt, central moiety: Gd, phase: II
A blood pool agent for magnetic resonancecoronary angiography and first pass myocardial perfusion imaging under development (Bracco Diagnostics Inc). The small molecules of gadolinium-based B22956 are bound after injection to large human serum albumin molecules in coronary vessels with the result of high vessel/muscle contrast.
Searchterm 'Magnetic Resonance' was also found in the following services:
FDA cleared and CE Mark 2011.
The Biograph mMR has a fully-integrated design for simultaneous PET/MRI imaging. The dedicated hardware includes solid-state, avalanche photodiode PET detector and adapted, PET-compatible MR coils.
The possibility of truly simultaneous operation allows the acquisition of several magnetic resonance imaging (MRI) sequences during the positron emission tomography (PET) scan, without increasing the examination time.
See also Hybrid Imaging.
Blood pool MRIcontrast agents with their longer intravascular circulation can be designed to be targeted to necrotic myocardium, to assess myocardial viability, or tumor directed to provide better diagnostic information for various tumors.
A disadvantage of the use of blood pool agents for MRA is that the separation of arteries and veins is more difficult because they are present in both and the overlapping of those vessels is disturbing. This can be solved by e.g. different MIP segmentation algorithms.